PF-114, a potent and selective inhibitor of native and mutated BCR/ABL is active against Philadelphia chromosome-positive (Ph+) leukemias harboring the T315I mutation-Reference-Cited by-同舟云学术

PF-114, a potent and selective inhibitor of native and mutated BCR/ABL is active against Philadelphia chromosome-positive (Ph+) leukemias harboring the T315I mutation

Published:2014-11-14 Issue:5 Volume:29 Page:1104-1114
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Mian A A,Rafiei A,Haberbosch I,Zeifman A,Titov I,Stroylov V,Metodieva A,Stroganov O,Novikov F,Brill B,Chilov G,Hoelzer D,Ottmann O G,Ruthardt M

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu2014326.pdf

Reference60 articles.

1. Hughes TP, Hochhaus A, Branford S, Muller MC, Kaeda JS, Foroni L et al. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood 2010; 116: 3758–3765.

2. Hoglund M, Sandin F, Hellstrom K, Bjoreman M, Bjorkholm M, Brune M et al. Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry. Blood 2013; 122: 1284–1292.

3. Talpaz M, Silver RT, Druker BJ, Goldman JM, Gambacorti-Passerini C, Guilhot F et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002; 99: 1928–1937.

4. Giles FJ, Kantarjian HM, le Coutre PD, Baccarani M, Mahon FX, Blakesley RE et al. Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase. Leukemia 2012; 26: 959–962.

5. Ottmann OG, Larson RA, Kantarjian HM, le Coutre PD, Baccarani M, Hochhaus A et al. Phase II study of nilotinib in patients with relapsed or refractory Philadelphia chromosome—positive acute lymphoblastic leukemia. Leukemia 2013; 27: 1411–1413.

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dose Justification for Asciminib in Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia with and Without the T315I Mutation;Clinical Pharmacokinetics;2024-09-07

2. FABRICATION, OPTIMIZATION AND IN VITRO CYTOTOXICITY EVALUATION OF DASATINIB MONOHYDRATE-LOADED NANOPARTICLES;International Journal of Applied Pharmaceutics;2024-09-07

3. Titania–Graphene Oxide Nanocomposite-Based Philadelphia-Positive Leukemia Therapy;ACS Applied Bio Materials;2024-06-20

4. Harmonizing the craft of crafting clinically endorsed small-molecule BCR-ABL tyrosine kinase inhibitors for the treatment of hematological malignancies;European Journal of Pharmaceutical Sciences;2024-02

5. CDK8/19 Inhibition Attenuates G1 Arrest Induced by BCR-ABL Antagonists and Accelerates Death of Chronic Myelogenous Leukemia Cells;2023-09-25